Lenalidomide in Multiple Myeloma: NCT07247097 Clinical Landscape Report 2026
Explore the PatSnap Life Sciences MCP marketplace
This Clinical Landscape Report was built with PatSnap Life Sciences MCP workflows. Clinical Trials MCP supplies protocol and result records, Drug & Asset MCP adds asset context, and Company & Deal Intelligence MCP resolves sponsor background. Use the same structured MCP building blocks in your research workflow.
Data snapshot: 15 October 2026. This strategic research report is not medical, regulatory or investment advice. Trial status and dates can change.
Phase 2
Clinical phase
Not yet recruiting
Recruitment status
not reported
Planned enrollment
2030-12-01
Primary-completion proxy
Executive view
NCT07247097 evaluates Lenalidomide in Multiple Myeloma. The disclosed sponsor is The Massachusetts General Hospital, the design is Interventional, and the geographic footprint is United States. The first listed primary endpoint is Proportion Patients who test Negative for Minimal Residual Disease (MRD) at 10^-5 after 4 Treatment Cycles, assessed over Day 1 of Cycle 1 (each cycle is 28 days) to Day 28 of Cycle 4..
The key landscape question is whether this protocol can generate a clinically interpretable signal relative to nearby programs. Phase alone is not a measure of evidence quality. Endpoint relevance, comparator choice, masking, enrollment feasibility, patient selection, country coverage and follow-up must be considered together.
PatSnap MCP Servers make this assessment reproducible by keeping protocol facts, result evidence, asset attributes and sponsor identity in separate structured calls.
How the MCP evidence stack was assembled
Clinical Trials MCP clinical_trial_fetch retrieved the design, outcomes, phase, status, enrollment, sponsor, countries and timing for NCT07247097 and selected peers. clinical_trial_result_fetch supplied detailed result records from the wider Multiple Myeloma landscape. Drug & Asset MCP drug_fetch was queried for Lenalidomide, while Company & Deal Intelligence MCP organization_fetch was queried for The Massachusetts General Hospital.
This separation reduces a common diligence error: treating a registry label, a company description or a result excerpt as if each represented the complete evidence package. Explore the source workflow at the PatSnap MCP marketplace.
Trial landscape table
| Trial | Asset / intervention | Phase / status | Sponsor | Geography | Primary endpoint | Readout proxy |
|---|---|---|---|---|---|---|
| NCT07247097 | Lenalidomide | Phase 2 / Not yet recruiting | The Massachusetts General Hospital | United States | Proportion Patients who test Negative for Minimal Residual Disease (MRD) at 10^-5 after 4 Treatment Cycles Day 1 of Cycle 1 (each cycle is 28 days) to Day 28 of Cycle 4. | 2030-12-01 |
| NCT07280013 | Cemsidomide | Phase 1 / Recruiting | C4 Therapeutics, Inc. | United States | Safety and tolerability of cemsidomide in combination with elranatamab Cycle 1 approximately 28 days | 2028-12-01 |
| NCT07280793 | BCMA CAR-T Cell(Xuzhou Medical University) | Early Phase 1 / Not yet recruiting | Xuzhou Medical University | Geography not reported | Biodistribution of 68Ga-NOTA-BCMA Baseline (pre-CAR-T), and at Day 6±2, Day 11±2, Day 21±2 post-CAR-T i… | 2027-12-30 |
| NCT07270263 | Rivaroxaban | Not Applicable / Recruiting | Medical University of Gdansk | Poland | Incidence of Venous Thromboembolism (VTE) 6 months from randomization | 2026-04-30 |
| NCT07266441 | Ramantamig | Phase 2 / Active, not recruiting | Janssen Research & Development LLC | South Korea, United States, Japan, China, Turkey, Poland, Italy, Israel | Overall Response Rate (ORR) Up to 2 years and 9 months | 2027-06-14 |
The table aligns endpoints, sponsors, phases, geographies and readout proxies. It is descriptive, not a head-to-head efficacy comparison. Differences in population, baseline risk, intervention schedule and follow-up can dominate apparent cross-trial differences.
Reproduce the trial-to-asset workflow with PatSnap MCP
Protocol design and endpoint interpretation
NCT07247097 is a Phase 2, not yet recruiting study with not reported planned participants. Allocation is Randomized, masking is None (Open Label), and the intervention model is Parallel Assignment.
The primary endpoint is “Proportion Patients who test Negative for Minimal Residual Disease (MRD) at 10^-5 after 4 Treatment Cycles” over “Day 1 of Cycle 1 (each cycle is 28 days) to Day 28 of Cycle 4..” The retrieved endpoint description is: Evaluated at 1 x 10\^-5 using next generation sequencing (NGS) to detect clonal sequences. The proportions will be compared using the Cochran-Mantzel-Haenszel test, stratified by the randomization stratification factors. A one-sided significance level of 0.05 will be used. Patients without successful baseline minimal residual disease (MRD) testing will not be evaluated for MRD response. Proportion patients who test negative for MRD at 10\^-5 after 4 treatment cycles will be compared between the elran-RVd lite arm and the dara-RVd lite arm..
Interpretation should test whether the endpoint captures a clinically meaningful change, whether its time horizon matches the proposed biology, and whether treatment discontinuation or missing data can bias the estimate. The planned enrollment of not reported should be assessed against expected effect size, event frequency, multiplicity, subgroup plans and attrition.
No named control drug was returned in the protocol field set. A placebo comparator can strengthen internal efficacy assessment, while an active comparator may better test clinical differentiation. Single-arm and open-label programs require greater weight on objective outcomes, independent assessment and external benchmarks.
Indexed readouts in the surrounding landscape
0 recent result records were selected as contextual evidence for Multiple Myeloma. These records do not establish direct evidence for NCT07247097 unless the registration number matches.
Indexed evidence status
No directly comparable result record was retrieved for this disease query. This is a monitoring gap, not evidence of absence.
Result fields should be reconciled with the source record before quantitative comparison. Population definitions, analysis sets, dose cohorts, estimands, confidence intervals, rescue therapy and follow-up can materially change the meaning of a numerical endpoint. Clinical Trials MCP supports repeatable refreshes as result records change.
Asset and sponsor context
Lenalidomide is indexed as Degradable Molecular Glue with CK1α x CRBN x IKZF1 x IKZF3 biology and a global stage of Approved. The asset profile lists Celgene Corp. as an originator or developer.
The Massachusetts General Hospital is indexed in an unreported country with the website http://www.massgeneral.org. Massachusetts General Hospital is a primary teaching hospital of Harvard Medical School and a biomedical research facility. The record lists 30 development-stage drug assets.
For execution diligence, monitor sponsor ownership, collaborator additions, site expansion, protocol amendments and enrollment revisions. A change in ownership or geography can alter operational confidence as well as the commercial meaning of a future readout.
Development white space
- Endpoint white space. Determine whether a more patient-relevant outcome, longer durability window or blinded central assessment would resolve uncertainty left by the current endpoint.
- Population white space. Test biomarker-defined, treatment-line or risk-stratified subgroups where effect size and unmet need could be clearer.
- Comparator white space. Identify whether the study can support differentiation against the current standard of care rather than only activity against baseline or placebo.
- Geographic white space. Assess whether the disclosed footprint supports recruitment, regulatory transferability and commercial generalizability.
- Sequencing white space. Clarify whether Lenalidomide is intended for monotherapy, combination, maintenance, rescue or an earlier treatment line.
White space should be framed as an unanswered development question, not merely an unoccupied mechanism label. A credible program closes a measurable clinical uncertainty with a design that can be executed and interpreted.
Strategic implications and next readouts
For sponsors, the endpoint hierarchy, safety window, enrollment pace and protocol amendment history should all support the same target product profile. Advancement criteria should be set before the readout and tied to clinical effect, uncertainty, tolerability and operational feasibility.
For business-development teams, differentiation may come from a sharper population, stronger comparator, more durable benefit, simpler delivery or clearer sequencing role. For investors, the central risk is evidence quality relative to time and capital, not the phase label in isolation.
Track recruitment status, enrollment changes, primary-completion timing, endpoint revisions, new result records, sponsor ownership and collaborator changes. Re-run the PatSnap MCP workflow when a surrogate becomes a clinical outcome, a single-country study expands, the comparator changes or a new result materially shifts the competitive benchmark.
Source trail and bottom line
Anchor trial: NCT07247097
Protocol source: https://clinicaltrials.gov/study/NCT07247097
MCP sources: Clinical Trials MCP (clinical_trial_fetch and clinical_trial_result_fetch); Drug & Asset MCP (drug_fetch); Company & Deal Intelligence MCP (organization_fetch).
Data snapshot: 15 October 2026.
Lenalidomide in Multiple Myeloma is best understood through the interaction of protocol design, surrounding readouts, asset context and sponsor execution. The current record makes Proportion Patients who test Negative for Minimal Residual Disease (MRD) at 10^-5 after 4 Treatment Cycles and 2030-12-01 the leading decision points.
Build and refresh clinical landscape reports with PatSnap MCP
